Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. - Wikidata - wikimedia - TriplyDB

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q37320504

about

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy Prostaglandin I2 Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes.Extra-glycaemic properties of empagliflozin.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors.Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.Time to target uric acid to retard CKD progression.SGLT2 inhibitors in the management of type 2 diabetes.SGLT2 Inhibitors: Benefit/Risk Balance.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials.Canagliflozin: A Review in Type 2 Diabetes.Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial.The grey zone of Hyperuricemia in chronic kidney disease.Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus.Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis.Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus.Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes.Physiology of Hyperuricemia and Urate-Lowering Treatments.Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea

P2860

Q26777529-8835CCCC-2E79-4365-8F2C-1E5A1C57C9E5 Q33845734-9D2346D8-7B76-4192-A5A6-CCDBB5B295F2 Q36373688-F1A994D9-07FF-4310-A35D-573AA424497F Q36820725-604F2918-152D-4B8A-ABC4-2DD30902FFFD Q37588847-B1DB5C08-BE96-494A-A592-75657639E1BD Q37661798-09323097-CEFF-4171-B732-0C1C64ED465F Q38494441-DCE597B6-4E64-4E3A-8A7C-C749FE53F14F Q38619164-335657EE-A835-433C-B1C0-4DFF5F832582 Q38715153-9D6AD7A5-04E0-434B-806E-04A154DC4132 Q38836416-3FAA72B5-B035-4907-BB24-5127D3A9BC41 Q38848997-94EAEAC6-4DD0-4C30-95A2-1E7D212BBEA2 Q38857523-C3875ADF-A565-4BBB-A7A2-472CA067F666 Q38931842-03E351F5-3D20-487B-B4D7-8E99F0FB417E Q39000587-3D345E4E-FABF-41C4-AB13-4C326848C192 Q39039079-CEB0E3F7-B2D4-4C13-9954-FF886FB5EC6D Q40068172-D7D442C7-2E46-498D-8F8F-F9C9D763EBF3 Q40081685-9F8A335E-AC67-4479-91C4-C255C10A9AB3 Q41026359-84232403-5653-49DB-A9A5-A4526070F6B4 Q42333924-9FCCD20C-2F83-41AD-A656-E7F18ACC82C4 Q42370483-10CBC205-8FAC-4E57-8203-F94EE3E44182 Q45025526-64824BF8-B312-4DFA-91BB-DD35818559C0 Q47115045-17ADB836-77DC-476E-B916-9239C117A466 Q47138528-86763E13-AD63-4E8B-87AF-87AE52D2E6A7 Q47419406-D03CB21A-BA1C-40B9-8EAC-095E7EB5BFDB Q47700645-78FDB82C-3944-42F5-8088-E274B8247A92 Q48227892-E47AC8E6-9982-4B81-A2BA-97FC931BDC5A Q51034590-8F106884-670A-4CCC-BE1F-59C0D36F4FC2 Q51833661-B5CBF5A7-D322-4D57-804E-27A6D87C9245 Q55163806-3AB9AFCA-72F6-47F4-B12E-B3D28C191A4C Q57214774-737AC28B-642E-46B4-B3B0-3DBFB18B6F0B

P2860

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

http://www.wikidata.org/entity/Q37320504

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 February 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@en

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@nl

type

label

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@en

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@nl

prefLabel

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@en

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@nl

P1433

Q37320504-56A1A628-DAD0-4C55-934A-8CFD62A431BF

P1476

Q37320504-11B75B0E-7DBF-4E54-8800-A1E0DD7AD021

P2093

Q37320504-13B49A5C-A909-47E1-B61A-019C5EC6BF96

Q37320504-2C917845-E52D-446A-85E9-446FBF027B5B

Q37320504-AAF5234F-F26E-4573-99DA-E65DB5A8671E

Q37320504-C828128F-F511-45E3-A94E-85201D142597

Q37320504-C83858E7-4716-4D1D-9AF1-7D89C98AF8B3

P2860

Q37320504-0832FA0A-637F-49BC-B9F1-2A270055F774

Q37320504-0E9442EB-E1E4-464B-811A-F4FF2F2E299C

Q37320504-281EC161-8139-43BB-B1B4-7B3441DDACFE

Q37320504-4D9785B8-FE1B-4A30-8053-102ACCCCF681

Q37320504-51BEC60A-29B7-4D4E-A9CE-B80EB26E5152

Q37320504-5218F0BA-D876-4F9C-BFA2-37391B9FB1C4

Q37320504-531BFAE7-79BA-41FD-9256-9BFE5B89622B

Q37320504-5393EA1C-A1D6-4AB4-A538-2FDD63E3CCC7

Q37320504-69247019-EF36-45FF-A7A7-4298052FAA7E

Q37320504-9928C776-601B-4076-AAAB-0B43DBCC36AB

P304

Q37320504-3EFB63C3-7D63-414C-8E9E-2718A8BCE93D

P31

Q37320504-1AB2481D-DBCA-46D1-83E0-43D4BD2DEB8C

P356

Q37320504-96F89499-5753-4920-9115-5326D78C8435

P433

Q37320504-64294554-2C64-418B-B48C-C3AA799B8173

P478

Q37320504-498C48ED-087A-446B-8463-A12216739143

P577

Q37320504-F83DC202-AEA4-4C3A-B9C1-2D1289DFB9F3

P698

Q37320504-B8478565-4593-4649-93A4-B9B0B750A7CC

P921

Q37320504-7318210C-4FA6-4AD5-B4BF-7A594C112405

Q37320504-F5A50694-9B09-455F-9963-2628491ED207

P932

Q37320504-C55F5FEC-BA88-4BB9-AFD8-6FFAB7B510EC

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.

@en

P2093

A Trujillo

http://www.w3.org/2001/XMLSchema#string

C V Damaraju

http://www.w3.org/2001/XMLSchema#string

G Meininger

http://www.w3.org/2001/XMLSchema#string

M J Davies

http://www.w3.org/2001/XMLSchema#string

U Vijapurkar

http://www.w3.org/2001/XMLSchema#string

P2860

SLC2A9 is a high-capacity urate transporter in humans

Management of hyperuricemia in gout: focus on febuxostat.

Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: a meta-analysis

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

P304

426-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12439

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25600248

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5054919

http://www.w3.org/2001/XMLSchema#string